PUBLICATION

Global Business Reports

AUTHORS

Margarita Todorova, Alexander Stonor, Ester Mbomio

United States Life Sciences 2023 - Digital Interactive

April 24, 2023

In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.

The above has not deterred an industry that is known for its innovation, and resilience, but mostly for the strength of its science. For pharma and biopharma firms – focused on cell and gene therapies, immune-oncology, or pioneering CNS breakthroughs – the focus will now be on embracing digitalization, navigating a changing regulatory and financial landscape, and tackling health inequalities. To support those breakthroughs, the CDMO, CMO, CRO, and services segment continued to strengthen in 2022.

In that context, Global Business Reports offers analysis derived from over 80 interviews with the industry’s most insightful, thought-provoking, and authoritative executives across the life sciences value chain, spanning 19 US states, and with firms from three continents with large footprints in America. Importantly, the report features GBR’s assessment of the trends that are likely to drive the industry in the coming months.

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENTLY PUBLISHED

MINPER 2023 - Perumin Official Investment Guide (Spanish Print Version)

GBR's MINPER: 2023 - PERUMIN Official Investment Guide, produced in strategic alliance with the Peruvian Institute of Mining Engineers, delves into the themes impacting the Peruvian mining industry. The report is produced after 130 interviews with leading authorities from government, industry associations, major producers, juniors, consultants, and technology and service providers.

MORE PREVIOUSLY PUBLISHED

MACIG

"Miners and contractors need to look at the full picture, putting into balance quality, governance, sustainability, and a lower total drilling cost against cheaper but uncompliant tools."

SUBSCRIBE TO OUR NEWSLETTER